click below
click below
Normal Size Small Size show me how
ANTIVIRAL
Question | Answer |
---|---|
Fusion inhibitors | Block ATTACHMENT: Maraviroc Block PENETRATION: Enfuvirtide |
Integrase inhibitors | Raltegravir |
Protease inhibitors | (-navir): Lopinavir, Atazanavir, Darunavir, Fosamprenavir, Saquinavir, Ritonavir, lndinavir |
Reverse transcriptase inhibitors | 1. NRTI´s 2. NNRTI´s |
NRTI´s (Nucleoside Reverse Transcriptase Inhibitors) | Tenofovir (TDF) Emtricitabine (FTC) Abacavir (ABC) Lamivudine (3TC) Zidovudine (ZDV,formerly AZT) Didanosine (ddl) Stavudine (d4T) |
NNRTI´s (Non-Nucleoside Reverse Transcriptase Inhibitors) | END E= Efavirenz N= Nevirapine D= Delavirdine |
Prevent maturation of new viruses | Protease inhibitors |
Protease inhibitor that can "boost" other drug concentrations by inhibiting cytochrome P-450. | Ritonavir |
Protease inhibitors; TOXICITY | 1. Hyperglycemia 2. GI intolerance (nausea, diarrhea) 3. Lipodystrophy. 4. Nephropathy 5. Hematuria (indinavir). |
NRTI that´s a nucleotide analog and does NOT have to be ACTIVATED | Tenofovir |
NRTI used for general prophylaxis and during pregnancy to reduce risk of fetal transmission. | Zidovudine (ZDV) |
NRTI´s (Nucleoside Reverse Transcriptase Inhibitors); TOXICITY | 1. Bone marrow suppression 2. Peripheral neuropathy 3. Lactic acidosis (nucleosides) 4. Rash (non-nucleosides) 5. Anemia (ZDV). 6. Pancreatitis (Didanosine) |
Bone marrow suppression caused by NRTI´s can be reversed with | Granulocyte colony stimulating factor (G-CSF) and erythropoietin |
Reversibly inhibiting HIV integrase. | Raltegravir (Integrase inhibitors) |
Raltegravir (Integrase inhibitors); TOXICITY | Hypercholesterolemia |
Binds gp41, inhibiting viral entry | Enfurvitide |
Skin reaction at injection site | Enfurvitide |
Binds CCR-5 on surface of T cells/monocytes, inhibiting interaction with gp120 | Maraviroc |
Inhibit influenza neuraminidase, decreasing the release of progeny virus. | Zanamivir, Oseltamivir |
Zanamivir, Oseltamivir; CLINICAL USE | BOTH Inlfuenza A and B |
Inhibits synthesis of guanine nucleotides by competitively inhibiting IMP dehydrogenase | Ribavirin |
RSV, Chronic Hepatitis C | Ribavirin |
Ribavirin; CLINICAL USE | RSV, Chronic Hepatitis C |
Ribavirin; TOXICITY | 1. Hemolytic anemia 2. Severe Teratogen |
Acyclovir (Nucleoside analog); MOA | Inhibits viral DNA polymerase by chain termination. |
Acyclovir; CLINICAL USE | 1. HSV and VZV 2. HSV encephalitis; Prophylaxis in immunocompromised patients. |
Prodrug of acyclovir, has better oral bioavailability. | Valacyclovir |
Herpes zoster | Famciclovir |
Acyclovir; TOXICITY | Obstructive crystalline nephropathy and acute renal failure if NOT adequately HYDRATED!!! |
Acyclovir; MECHANISM OF RESISTANCE | Mutated viral thymidine kinase |
CMV | Ganciclovir, Foscarnet |
Ganciclovir; TOXICITY | MORE toxic to host enzymes than Acyclovir 1. Leukopenia 2. Neutropenia 3. Thrombocytopenia 4. Renal toxicity |
MORE toxic to host enzymes than Acyclovir | Ganciclovir |
Foscarnet; MOA | Pyrophosphate analog |
Inhibit viral Nucleic Acid synthesis | 1. Guanine nucleotide synthesis: -Ribavirin (RSV, HCV) 2. Viral DNA Polymerase inhibitors: -Foscarnet (CMV) -Cidofovir (HSV Acyclovir resistant) 3. Guanosine analogs: -Acyclovir (HSV, VZV) -Ganciclovir (CMV) |
Foscarnet; CLINICAL USE | 1. CMV retinitis in immunocompromised patients when ganciclovir fails 2. Acyclovir-resistant HSV. |
Foscarnet; MECHANISM OF RESISTANCE | Mutated DNA polymerase |
What decreases Cidofovir toxicity | Coadminister with Probenecid and IV saline |
Glycoproteins synthesized by virus-infected cells | Interferons |
Interferons; MOA | block replication of both RNA and DNA viruses. |
IFN-Alpha | 1. Chronic Hepatitis B and C 2. Kaposi sarcoma 3. Hairy cell leukemia 4. Condyloma acuminatum 5. Renal cell carcinoma 6. Malignant melanoma |
IFN-Beta | Multiple sclerosis |
IFN-Gamma | Chronic granulomatous disease |